Biomarin Pharmaceutical Inc (BMRN)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	2,249,985	2,152,148	2,047,670	1,929,538	1,858,176	1,754,938	1,686,510	1,629,885	1,575,812	1,523,342	1,440,300	1,404,301	1,356,936	1,352,560	1,329,619	1,282,275	1,298,545	1,328,331	1,411,148	1,391,139
Revenue (ttm)	US$ in thousands	2,830,220	2,731,722	2,563,532	2,443,023	2,373,030	2,261,604	2,184,719	2,123,138	2,059,481	1,999,471	1,903,678	1,871,615	1,827,451	1,829,463	1,891,778	1,815,339	1,822,817	1,822,364	1,813,337	1,772,797
Gross profit margin		79.50%	78.78%	79.88%	78.98%	78.30%	77.60%	77.20%	76.77%	76.52%	76.19%	75.66%	75.03%	74.25%	73.93%	70.28%	70.64%	71.24%	72.89%	77.82%	78.47%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $2,249,985K ÷ $2,830,220K
= 79.50%

Biomarin Pharmaceutical Inc's gross profit margin has shown stability and improvement over the analyzed period. Starting at 78.47% in March 2020, the margin slightly decreased to 70.28% by June 2021 but then gradually increased to reach 79.50% by December 2024. This indicates the company's ability to effectively manage its production costs relative to its revenue, leading to a higher percentage of revenue retained as gross profit. The consistent upward trend in the gross profit margin suggests improved operational efficiency and potentially better pricing strategies. Overall, Biomarin Pharmaceutical Inc's gross profit margin reflects a positive trajectory, showcasing its strong financial performance in generating profits from its core operations.